David Snead

David Snead

Company: Mirati Therapeutics

Job title: Associate Director, Chemical Development


Enabling Atroposelective Syntheses via Simultaneous Processing of Antagonistic Chemical Events (SPACE) 9:30 am

• Optical resolution is a reliable method for separation of atropisomers but it is plagued by a maximum-yield of 50% • Axes of chirality can be thermally epimerized but this conflicts with conditions required for crystallization (cooling) • Continuous flow can be applied to resolve these competing needs, resulting in high-yielding synthesis of atropisomers which…Read more

day: Day One